52240-22-9

Upstream product

• 4619-20-9 3-(4-methylbenzoyl)propionic acid 
• 79822-14-3 (3-nitro-4-tolyl)-4-oxobutanoic acid 

Downstream Products

• 122334-02-5 4-(3-methoxy-4-methylphenyl)butanoic acid 
• 61495-09-8 4-(3-methoxy-4-methyl-phenyl)-4-oxo-butyric acid 
• 56872-34-5 3-(3-hydroxy-4-methylbenzoyl)-propionic acid 

Relevant academic research and scientific papers

HYBRID NECROPTOSIS INHIBITORS

The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.

Benzenesulfonamide derivatives and processes for their manufacture

Benzenesulfonamide derivatives as defined in the specification have an outstanding salidiuretic action. Some of the compounds exhibit a significant increase in the excretion of uric acid and the uric acid clearance. They are distinguished by a long-lastin